C2i Genomics vs MeMed
C2i Genomics vs MeMed, compared side by side on 22 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: C2i Genomics is on 62/100 and MeMed on 61/100.
Where each one leads
C2i Genomics
- domain rating: 63/100 against 46/100
MeMed
- agent readiness: 35/100 against 30/100
- headcount: 99 against 17
- headcount growth: -8.4% against -20.8%
- funding raised: $196M against $112M
- LinkedIn following: 21,207 against 6,366
At a glance
| Measure | C2i Genomics | MeMed |
|---|---|---|
| What it is | Comprehensive whole-genome monitoring for cancer recurrence and progression. | MeMed develops and commercializes host immune response diagnostic solutions to address complex clinical dilemmas and improve patient outcomes. |
| Category | Healthcare, Genomics, Cancer, Tumor Detection | Healthcare, Blood, Diagnostics, MedTech |
| Sells toBusiness model | B2B | B2B, B2G |
| Offering | Software | Software, Hardware |
| Founded | 2018 | 2009 |
| Headquarters | Tel Aviv, Israel | Tirat Carmel, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | C2i Genomics | MeMed |
|---|---|---|
| Employees | 17 | 99 |
| Headcount growthLast 12 months | -20.8% | -8.4% |
| Total funding | $112M | $196M |
| Latest round | Series B | Series E |
| LinkedIn followers | 6,366 | 21,207 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | C2i Genomics | MeMed |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 61/100 |
| Traction | 53/100 | 60/100 |
| Team | 90/100 | 70/100 |
| Search visibility | 35/100 | 29/100 |
| Quality | 65/100 | 65/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (30/100) | F (35/100) |
| Domain ratingLink authority, 0-100 | 63/100 | 46/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | C2i Genomics | MeMed |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Bootstrap | Jquery |
| Analytics | Google Analytics 4, Google Tag Manager | Google Analytics 4, Google Tag Manager |
C2i Genomics vs MeMed: common questions
Which is better, C2i Genomics or MeMed?
On our 0-100 score C2i Genomics rates higher (62/100 against 61/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 22 data points above: read the rows that match what you are buying for.
How do C2i Genomics and MeMed compare on the numbers?
C2i Genomics leads on domain rating (63/100 against 46/100). MeMed leads on agent readiness (35/100 against 30/100), headcount (99 against 17), headcount growth (-8.4% against -20.8%), funding raised ($196M against $112M), LinkedIn following (21,207 against 6,366).
Read the full C2i Genomics review and pricing or the MeMed review and pricing. You can also browse other C2i Genomics alternatives we track.